NewsRx Logo Login/Signup
Home Newsletters Products Library About Us Contact -- Search NewsRx

NewsRx | Free Trials
Advertisement
VerticalNews | Global Warming
NewsRx | Free Newsletters
 
----------
------------
NewsRx on Facebook
-----
NewsRx Passes
Press Release Submissions
PR Login
-----
2008 Award Logo
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
-----
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.

Security by Verisign

Meconium Aspiration


Return to Library

Free Meconium Aspiration Articles


Investigators at University Children's Hospital zero in on perinatology



2009 JUN 25 - (NewsRx.com) -- "Surfactant treatment in preterm infants and term newborns with (acute respiratory distress syndrome) ARDS-like severe respiratory failure has become part of an individualized treatment strategy in many intensive care units around the world. These babies constitute heterogeneous groups of gestational ages, lung maturity, as well as of the underlying disease processes and postnatal interventions," scientists in Wurzburg, Germany report.

"The pathophysiology of respiratory failure in preterm infants is characterized by a combination of primary surfactant deficiency and surfactant inactivation as a result of plasma proteins leaking into the airways from areas of epithelial disruption and injury. Various pre- and postnatal factors, such as exposure to chorioamnionitis, pneumonia, sepsis and asphyxia, induce an injurious inflammatory response in the lungs of preterm infants, which may subsequently affect surfactant function, synthesis and alveolar stability. Surfactant inactivation-and dysfunction-is also a hallmark in newborns with meconium aspiration syndrome (MAS), pneumonia and other disorders affecting the pulmonary function. Although for the majority of suggested indications no data from randomized controlled trials exist, a surfactant replacement that counterbalances surfactant inactivation seems to improve oxygenation and lung function in many babies with ARDS without any apparent negative side effects. Newborns with MAS will definitely benefit from a reduced need for extracorporeal membrane oxygenation (ECMO). Clinical experience seems to justify surfactant treatment in neonates with ARDS," wrote J. Wirbelauer and colleagues, University Children's Hospital.

The researchers concluded: "Journal of Perinatology (2009) 29, S18-S22; doi:10.1038/jp.2009.30'."

Wirbelauer and colleagues published their study in the Journal of Perinatology (The role of surfactant treatment in preterm infants and term newborns with acute respiratory distress syndrome. Journal of Perinatology, 2009;29(Suppl. 2):S18-S22).

For additional information, contact C.P. Speer, University Children's Hospital, Josef Schneider St. 2, D-97080 Wurzburg, Germany.

The publisher's contact information for the Journal of Perinatology is: Nature Publishing Group, 75 Varick St., 9TH Flr, New York, NY 10013-1917, USA.

Keywords: Germany, Wurzburg, Life Sciences, Pediatrics, Septicemia, Sepsis, Bloodstream Infection, Chorioamnionitis, Asphyxia, Perinatology, Physiology, University Children's Hospital.

This article was prepared by Hospital Law Weekly editors from staff and other reports. Copyright 2009, Hospital Law Weekly via NewsRx.com.

NewsRx NewsRx NewsRx
-----------------------
PR Login